Current Hepatitis Reports

, Volume 6, Issue 2, pp 60–67

Managing hepatitis C in users of illicit drugs

  • Brian R. Edlin
  • Michael R. Carden
  • Stephen J. Ferrando
Article

Abstract

Persons who inject illicit drugs are the group most severely affected by the hepatitis C epidemic but the least likely to receive treatment. Controlling the epidemic will require developing strategies for effectively treating drug users. A growing number of reports have shown that a substantial proportion of drug users treated for hepatitis C can achieve sustained virologic responses even if they have psychiatric comorbidity and even if they continue to use drugs while receiving hepatitis C treatment. Successfully treating hepatitis C in injection drug users requires collaboration between those with expertise in hepatitis and those with expertise in caring for substance users. Careful attention to management of adverse effects and strong links with mental health services are important. Further research is needed to better define which patients can be successfully treated and the program elements that are critical for success. In the meantime, substantial progress can be made using current knowledge if appropriate resources are brought to bear.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements19:1–46. Accessed at http://consensus.nih.gov/2002/2002HepatitisC2002116html.htm on March 16, 2007.
  2. 2.
    Strader DB, Wright T, Thomas DL, Seeff LB: AASLD practice guideline: diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147–1171.PubMedCrossRefGoogle Scholar
  3. 3.
    Veldt BJ, Saracco G, Boyer N, et al.: Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004, 53:1504–1508.PubMedCrossRefGoogle Scholar
  4. 4.
    Edlin BR, Carden MR: Injection drug users: the overlooked core of the hepatitis C epidemic. Clin Infect Dis 2006, 42:673–676.PubMedCrossRefGoogle Scholar
  5. 5.
    Thomas DL, Vlahov D, Solomon L, et al.: Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995, 74:212–220.CrossRefGoogle Scholar
  6. 6.
    Lorvick J, Kral AH, Seal K, et al.: Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health 2001, 91:46–47.PubMedGoogle Scholar
  7. 7.
    Garfein RS, Doherty MC, Monterroso ER, et al.: Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 18(Suppl 1):S11–S19.PubMedGoogle Scholar
  8. 8.
    Hahn JA, Page-Shafer K, Lum PJ, et al.: Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 2001, 34:180–187.PubMedCrossRefGoogle Scholar
  9. 9.
    Thorpe LE, Ouellet LJ, Hershow R, et al.: Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002, 155:645–653.PubMedCrossRefGoogle Scholar
  10. 10.
    Judd A, Hickman M, Jones S, et al.: Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ 2005, 330:24–25.PubMedCrossRefGoogle Scholar
  11. 11.
    Edlin BR: Hepatitis C prevention and treatment for substance users in the United States: acknowledging the elephant in the living room. Int J Drug Policy 2004, 15:81–91.PubMedCrossRefGoogle Scholar
  12. 12.
    Stein MD, Maksad J, Clarke J: Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend 2001, 61:211–215.PubMedCrossRefGoogle Scholar
  13. 13.
    Edlin BR, Kresina TF, Raymond DB, et al.: Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 2005, 40(Suppl 5):S276–S285.PubMedCrossRefGoogle Scholar
  14. 14.
    Chappel JN, Schnoll SH: Physician attitudes. Effect on the treatment of chemically dependent patients. JAMA 1977, 237:2318–2319.PubMedCrossRefGoogle Scholar
  15. 15.
    Groves JE: Taking care of the hateful patient. N Engl J Med 1978, 298:883–887.PubMedGoogle Scholar
  16. 16.
    Gorlin R, Zucker HD: Physicians’ reactions to patients. A key to teaching humanistic medicine. N Engl J Med 1983, 308:1059–1063.PubMedCrossRefGoogle Scholar
  17. 17.
    Gerbert B, Maguire BT, Bleecker T, et al.: Primary care physicians and AIDS. Attitudinal and structural barriers to care. JAMA 1991, 266:2837–2842.PubMedCrossRefGoogle Scholar
  18. 18.
    Ding L, Landon BE, Wilson IB, et al.: Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users. Arch Intern Med 2005, 165:618–623.PubMedCrossRefGoogle Scholar
  19. 19.
    O’Connor PG, Selwyn PA, Schottenfeld RS: Medical care for injection-drug users with human immunodeficiency virus infection. N Engl J Med 1994, 331:450–459.PubMedCrossRefGoogle Scholar
  20. 20.
    Batki SL, Sorensen JL: Care of injection drug users with HIV. In HIV InSite Knowledge Base. Edited by Peiperl L, Coffey S, Bacon O, Volberding P. San Francisco: University of California; 1998. Accessed at http://hivinsite.ucsf.edu/InSite?page=kb-00&doc=kb-03-03-06 on February 2, 2007.Google Scholar
  21. 21.
    Backmund M, Meyer K, Von Zielonka M, Eichenlaub D: Treatment of hepatitis C infection in injection drug users. Hepatology 2001, 34:188–193.PubMedCrossRefGoogle Scholar
  22. 22.
    Jowett SL, Agarwal K, Smith BC, et al.: Managing chronic hepatitis C acquired through intravenous drug use. QJM 2001, 94:153–158.PubMedCrossRefGoogle Scholar
  23. 23.
    Neri S, Bruno CM, Abate G, et al.: Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. Clin Ther 2002, 24:1627–1635.PubMedCrossRefGoogle Scholar
  24. 24.
    Schaefer M, Schmidt F, Folwaczny C, et al.: Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003, 37:443–451.PubMedCrossRefGoogle Scholar
  25. 25.
    Van Thiel DH, Anantharaju A, Creech S: Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol 2003, 98:2281–2288.PubMedCrossRefGoogle Scholar
  26. 26.
    Cournot M, Glibert A, Castel F, et al.: Management of hepatitis C in active drugs users: experience of an addiction care hepatology unit. Gastroenterol Clin Biol 2004, 28:533–539.PubMedGoogle Scholar
  27. 27.
    Mauss S, Berger F, Goelz J, et al.: A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004, 40:120–124.PubMedCrossRefGoogle Scholar
  28. 28.
    Huber M, Weber R, Oppliger R, et al.: Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial. Infection 2005, 33:25–29.PubMedCrossRefGoogle Scholar
  29. 29.
    Dalgard O: Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis 2005, 40(Suppl 5):S336–S338.PubMedCrossRefGoogle Scholar
  30. 30.
    Matthews G, Kronborg IJ, Dore GJ: Treatment for hepatitis C virus infection among current injection drug users in Australia. Clin Infect Dis 2005, 40(Suppl 5):S325–S329.PubMedCrossRefGoogle Scholar
  31. 31.
    Litwin AH, Soloway I, Gourevitch MN: Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin Infect Dis 2005, 40(Suppl 5):S339–S345.PubMedCrossRefGoogle Scholar
  32. 32.
    Clanon KA, Johannes Mueller J, Harank M: Integrating treatment for hepatitis C virus infection into an HIV clinic. Clin Infect Dis 2005, 40(Suppl 5):S362–S366.PubMedCrossRefGoogle Scholar
  33. 33.
    Bargiacchi O, Audagnotto S, Garazzino S, De Rosa FG: Treatment of acute C hepatitis in intravenous drug users. J Hepatol 2005, 43:186–187.PubMedCrossRefGoogle Scholar
  34. 34.
    Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN: The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat 2005, 29:159–165.PubMedCrossRefGoogle Scholar
  35. 35.
    Robaeys G, Van Vlierberghe H, Mathei C, et al.: Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol 2006, 18:159–166.PubMedCrossRefGoogle Scholar
  36. 36.
    Matthews AM, Fireman M, Zucker B, et al.: Relapse to opioid use after treatment of chronic hepatitis C with pegylated interferon and ribavirin. Am J Psychiatry 2006, 163:1342–1347.PubMedCrossRefGoogle Scholar
  37. 37.
    Sylvestre DL, Smith A, Barrett L, Cohen JB: Integrated drug and HCV treatment for street-recruited heroin users [abstract]. Hepatology 2006, 44(4 Suppl 1):221A (Abstract 88).Google Scholar
  38. 38.
    Jeffrey GP, MacQuillan G, Chua F, et al.: Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants. Hepatology 2007, 45:111–117.PubMedCrossRefGoogle Scholar
  39. 39.
    Sylvestre DL, Clements BJ, Malibu Y: Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. Eur J Gastroenterol Hepatol 2006, 18:1057–1063.PubMedCrossRefGoogle Scholar
  40. 40.
    Substance Abuse and Mental Health Services Administration, US Department of Health and Human Services: National Survey on Drug Use and Health. Washington, DC: US Department of Health and Human Services; 2005. Accessed at http://oas.samhsa.gov/NSDUH/2k5NSDUH/tabs/Sect1peTabs1to66.htm on February 2, 2007.
  41. 41.
    Effective medical treatment of opiate addiction. NIH Consens Statement Online 1997, 15(6):1–38. Accessed at http://consensus.nih.gov/1997/1998TreatOpiateAddiction108html.htm on February 7, 2007.
  42. 42.
    Gowing L, Farrell M, Bornemann R, Ali R: Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2004, CD004145.Google Scholar
  43. 43.
    Fudala PJ, Bridge TP, Herbert S, et al.: Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003, 349:949–958.PubMedCrossRefGoogle Scholar
  44. 44.
    McHutchison JG, Bartenschlager R, Patel K, Pawlotsky JM: The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. J Hepatol 2006, 44:411–421.PubMedCrossRefGoogle Scholar
  45. 45.
    Jaeckel E, Cornberg M, Wedemeyer H, et al.: Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001, 345:1452–1457.PubMedCrossRefGoogle Scholar
  46. 46.
    Lucas GM, Cheever LW, Chaisson RE, Moore RD: Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001, 27:251–259.PubMedGoogle Scholar
  47. 47.
    Conrad S, Garrett LE, Cooksley WG, et al.: Living with chronic hepatitis C means ‘you just haven’t got a normal life any more’. Chronic Illn 2006, 2:121–131.PubMedGoogle Scholar
  48. 48.
    Laskus T, Radkowski M, Adair DM, et al.: Emerging evidence of hepatitis C virus neuroinvasion. AIDS 2005, 19(Suppl 3):S140–S144.PubMedCrossRefGoogle Scholar
  49. 49.
    Ryan EL, Morgello S, Isaacs K, et al.: Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology 2004, 62:957–962.PubMedGoogle Scholar
  50. 50.
    Dieperink E, Willenbring M, Ho SB: Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000, 157:867–876.PubMedCrossRefGoogle Scholar
  51. 51.
    Mason BJ, Kocsis JH, Melia D, et al.: Psychiatric comorbidity in methadone maintained patients. J Addict Dis 1998, 17:75–89.PubMedCrossRefGoogle Scholar
  52. 52.
    Dore GJ, Thomas DL: Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection. Semin Liver Dis 2005, 25:18–32.PubMedCrossRefGoogle Scholar
  53. 53.
    Proust B, Dubois F, Bacq Y, et al.: Two successive hepatitis C virus infections in an intravenous drug user. J Clin Microbiol 2000, 38:3125–3127.PubMedGoogle Scholar
  54. 54.
    Backmund M, Meyer K, Edlin BR: Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004, 39:1540–1543.PubMedCrossRefGoogle Scholar
  55. 55.
    Edlin BR: Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002, 36(5 Suppl 1):S210–S219.PubMedCrossRefGoogle Scholar
  56. 56.
    Rich JD, Macalino GE, McKenzie M, et al.: Syringe prescription to prevent HIV infection in Rhode Island: a case study. Am J Public Health 2001, 91:699–700.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2007

Authors and Affiliations

  • Brian R. Edlin
    • 1
  • Michael R. Carden
  • Stephen J. Ferrando
  1. 1.Center for the Study of Hepatitis CWeill Medical College of Cornell University, New York-Presbyterian HospitalNew YorkUSA

Personalised recommendations